Joint technical-scientific recommendation: nonavalent human papillomavirus vaccination for the prevention of oropharyngeal cancer

Authors

DOI:

https://doi.org/10.5327/2237-4574-236

Abstract

***

References

Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa

–2028: Incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2025.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J,

et al. A 9-valent HPV vaccine against infection and intraepithelial

neoplasia in women. N Engl J Med. 2015;372(8):711-23. https://doi.

org/10.1056/nejmoa1405044

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA,

et al. Reduced prevalence of oral human papillomavirus (HPV) 4

years after bivalent HPV vaccination in a randomized clinical trial in

Costa Rica. PLoS One. 2013;8(7):e68329. https://doi.org/10.1371/

journal.pone.0068329

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E,

et al. Human papillomavirus and rising oropharyngeal cancer incidence

in the United States. J Clin Oncol. 2011;29(32):4294-301. https://

doi.org/10.1200/jco.2011.36.4596

Published

2026-08-11

How to Cite

1.
Nunes AAA, de Matos FM, Tso FK, Teles HFM, Chaves JHB, Speck NM de G. Joint technical-scientific recommendation: nonavalent human papillomavirus vaccination for the prevention of oropharyngeal cancer. Rev Bras Patol Trato Genit Inferior [Internet]. 2026 Aug. 11 [cited 2026 Aug. 29];10(01). Available from: https://rbptgi.emnuvens.com.br/revista/article/view/236

Issue

Section

Technical Recommendations